Literature DB >> 10840276

Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions.

J E Simpson1, J Newcombe, M L Cuzner, M N Woodroofe.   

Abstract

The recruitment of leucocytes to sites of inflammation is an important feature of multiple sclerosis (MS) pathology. Chemokines are involved in the activation and specific directional migration of monocytes and T-lymphocytes to sites of inflammation. Using immunocytochemistry, the expression of the alpha-chemokines, interferon (IFN)-gamma-inducible protein-10 (IP-10) and monokine induced by IFN-gamma (Mig), and their receptor CXCR3 have been examined in post-mortem central nervous system (CNS) tissue from MS cases at different stages of lesion development. In actively demyelinating lesions both IP-10 and Mig protein were predominantly expressed by macrophages within the plaque and by reactive astrocytes in the surrounding parenchyma. CXCR3 was expressed by T cells and by astrocytes within the plaque. Interferon-gamma may stimulate glial cells to express IP-10 and Mig, which continue the local inflammatory response by selectively recruiting activated T-lymphocytes into the CNS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840276     DOI: 10.1046/j.1365-2990.2000.026002133.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  49 in total

Review 1.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

2.  T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking.

Authors:  P Kivisäkk; C Trebst; Z Liu; B H Tucky; T L Sørensen; R A Rudick; M Mack; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

3.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 4.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 5.  Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS.

Authors:  Benjamin D Clarkson; Erika Héninger; Melissa G Harris; JangEun Lee; Matyas Sandor; Zsuzsanna Fabry
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 6.  Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.

Authors:  Yong-Jing Gao; Ru-Rong Ji
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

Review 7.  Neuronal chemokines: versatile messengers in central nervous system cell interaction.

Authors:  A H de Haas; H R J van Weering; E K de Jong; H W G M Boddeke; K P H Biber
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

8.  1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization.

Authors:  Inna V Grishkan; Amanda N Fairchild; Peter A Calabresi; Anne R Gocke
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

Review 9.  Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.

Authors:  Meysam Gachpazan; Sadra Habbibirad; Hoda Kashani; Tannaz Jamialahmadi; Hamid Reza Rahimi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Authors:  George P Christophi; Chad A Hudson; Ross C Gruber; Christoforos P Christophi; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2008-01-21       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.